LIV-GAMMA SN Inj.10% (SKP-0110)
/ SK Discovery
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 05, 2022
A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP)
(clinicaltrials.gov)
- P3 | N=34 | Completed | Sponsor: SK Plasma Co., Ltd.
New P3 trial • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura
1 to 1
Of
1
Go to page
1